Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-054
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2017 Planned End Date changed from 1 Dec 2017 to 19 Jul 2025.
- 16 Feb 2017 Planned End Date changed from 1 Aug 2024 to 1 Dec 2017.